Clinical Trial Update: Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

The trial evaluated a three-drug regimen (docetaxel, epirubicin, bevacizumab) as first-line therapy for metastatic HER2-negative breast cancer, and the Phase 1/…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• DOCETAXEL (DOCETAXEL)
• Epirubicin (epirubicin)

Snippet

Sponsor: Hellenic Oncology Research Group | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED